"Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.

Bispecific T-cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B-cell lymphomas and multiple myeloma otherwise resistant to other therapies, but the duration of response to these treatments is limited in time. Allogeneic stem cell transplantation is a potentially curative approach for those disorders, although its indication is limited to patients who achieve remission. With no established strategies to improve the "graft-versus-tumor effect" available, relapses still account for most posttransplant failures. Here, we report, to our knowledge, the first case in literature of a successful treatment with glofitamab, a CD20X2/CD3 BiTE, in a posttransplant relapse of mantle cell lymphoma with central nervous disease involvement. We propose the combination of BiTEs and allogeneic transplant as an integrated and sequential immunologic approach to be tested in clinical trials.